Maxigen Biotech Inc
TWSE:1783

Watchlist Manager
Maxigen Biotech Inc Logo
Maxigen Biotech Inc
TWSE:1783
Watchlist
Price: 46.9 TWD Market Closed
Market Cap: 4.2B TWD
Have any thoughts about
Maxigen Biotech Inc?
Write Note

Maxigen Biotech Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Maxigen Biotech Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Maxigen Biotech Inc
TWSE:1783
Additional Paid In Capital
NT$309m
CAGR 3-Years
6%
CAGR 5-Years
28%
CAGR 10-Years
5%
G
Grape King Bio Ltd
TWSE:1707
Additional Paid In Capital
NT$2.9B
CAGR 3-Years
0%
CAGR 5-Years
24%
CAGR 10-Years
93%
Maywufa Co Ltd
TWSE:1731
Additional Paid In Capital
NT$192.4m
CAGR 3-Years
1%
CAGR 5-Years
2%
CAGR 10-Years
0%
Chlitina Holding Ltd
TWSE:4137
Additional Paid In Capital
NT$1.9B
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
3%
No Stocks Found

Maxigen Biotech Inc
Glance View

Market Cap
4.2B TWD
Industry
Consumer products

Maxigen Biotech, Inc. engages in the research, development, manufacturing, and sales of biomedical materials and beauty care products. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2011-05-18. The firm operates through two main segments. The Consumer Products segment is mainly engaged in the wholesales of cleansing products, facial care products, medical beauty products and others. The Biomedical Products is mainly involved in the manufacture and sales of Formagraft collagen and ceramic composite material products, Foramic ceramic bone feed materials, Artiaid hyaluronic acid joint injection products, ViscAid ophthalmology viscoelastic agents, as well as SurgiAid wound collagen materials and others.

Intrinsic Value
30.44 TWD
Overvaluation 35%
Intrinsic Value
Price

See Also

What is Maxigen Biotech Inc's Additional Paid In Capital?
Additional Paid In Capital
309m TWD

Based on the financial report for Sep 30, 2024, Maxigen Biotech Inc's Additional Paid In Capital amounts to 309m TWD.

What is Maxigen Biotech Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
5%

Over the last year, the Additional Paid In Capital growth was 4%. The average annual Additional Paid In Capital growth rates for Maxigen Biotech Inc have been 6% over the past three years , 28% over the past five years , and 5% over the past ten years .

Back to Top